# Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL

> **NCT00344786** · PHASE1 · TERMINATED · sponsor: **Biogen** · enrollment: 15 (actual)

## Conditions studied

- B-Cell Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** CNF2024 (BIIB021)

## Key facts

- **NCT ID:** NCT00344786
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-02
- **Primary completion:** 2008-07
- **Final completion:** 2008-09
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Sponsor's decision
- **Last updated:** 2009-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00344786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00344786, "Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00344786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*